<DOC>
	<DOC>NCT01174160</DOC>
	<brief_summary>This study will investigate if treatment with vernakalant hydrochloride (MK-6621) results in a greater proportion of patients with treatment-induced conversion of Atrial Fibrillation to sinus rhythm compared to placebo.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)</brief_title>
	<detailed_description>Amendment 4 of the protocol revised the planned enrollment to 123 participants and removed China as one of the countries participating in the study.</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Abstinent or willing to use 2 acceptable methods of birth control Patient has an atrial arrhythmia with dysrhythmic symptoms Patient is receiving adequate anticoagulant therapy Patient has stable blood pressure Patient weighs between 45 and 136 kg (99 and 300 lbs) Patient is adequately hydrated Patient is pregnant, breastfeeding, or expecting to become pregnant during the study Patient routinely consumes more than 2 alcoholic drinks per day Patient has known or suspected prolonged QT, familial long QT syndrome, previous Torsades de Pointes, Brugada syndrome Patient has known bradycardia, advanced AV block, or sicksinus syndrome, unless controlled by a pacemaker Patient has severe aortic stenosis Patient has atrial flutter Patient has Class IV congestive heart failure (CHF) Patient has had a myocardial infarction (MI) or acute coronary syndrome (ACS) Patient has had cardiac surgery within 30 days Patient has known atrial thrombus Patient has reversible causes of Atrial Fibrillation Patient has failed electrical cardioversion during current episode of Atrial Fibrillation Patient has uncorrected electrolyte imbalance Patient has clinical evidence of digoxin toxicity Patient has received certain antiarrhythmic drugs or intravenous amiodarone within 7 days Patient is known to be HIV positive Patient has a history of cancer within the past 5 years, except for certain skin or cervical cancers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
</DOC>